Globus Medical Inc.

“Enabling Technologies showed a modest bounce back in Q2, while we remain focused on accelerating deal timelines from our pipeline to make robotic assisted surgery the standard of care moving ahead.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Our long-term strategy remains unchanged, as we continue to focus on new product launches, driving organic growth, competitive rep recruiting to expand our sales force and robotic account pull through.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Our second quarter results are a testament of achieving operational efficiency, while focusing on long-term, profitable growth,” commented Kyle Kline, CFO.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

 In addition, for the period ended June 3 0 , 2025 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments , bargain purchase gains, certain valuation allowance releases on deferred tax assets , and the tax effects of all of the foregoing adjustments.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

 In addition, for the period ended June 3 0 , 2025 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments , bargain purchase gains, certain valuation allowance releases on deferred tax assets , and the tax effects of all of the foregoing adjustments.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.

SEC original ↗Globus Medical Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025